Sales growth of prescribed medicines has slowed to single digits, ending the double-digit expansion the pharmaceutical market enjoyed for years before the pandemic, as rising production costs and currency depreciation collide with prolonged inflation.

Bangladesh’s pharmaceutical companies risk losing the chance to produce at least 15 costly biologic drugs royalty-free

Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its continuous product development and expanding global footprint.

Denmark’s IFU will invest $12.5 million in pharmacy chain AKS Khan Pharmaceuticals for the expansion of the latter’s network, targeting to cater to 8 million patients annually within three years.

The pharmaceutical sector of Bangladesh has achieved many milestones over the past 14 years. Not only do local companies now meet 90 percent of the country’s demand for medicines, but the products are also exported to around 150 countries, fetching hundreds of millions of dollars.